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Abstract
Background: The management of acute febrile illnesses places a heavy burden on clinical services in many low-
and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically
indistinguishable and, in the absence of diagnostic tests, the ‘just-in-case’ use of antibiotics by many health workers
has become common practice, which has an impact on drug-resistant infections.
Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to
outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and
reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate
diagnostic tests, clinical algorithms, and training and communication (intervention package)?
Methods: We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package
on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-
specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention
package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana,
India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We
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considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by
ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific
ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute
febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new
diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data
of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies
will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion.
Discussion: This study is expected to generate vital evidence needed to inform policy decisions on the role of
rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of
antimicrobial resistance in LMICs.
Trial registration: Clinicaltrials.gov NCT04081051. Registered on 6 September 2019. Protocol version 1.4 dated 20
December 2019
Keywords: Febrile illness, Antimicrobial resistance, Antibiotic prescription, Randomized controlled trial, Outpatient
fever management
Background
The World Health Organization (WHO) considers anti-
microbial resistance (AMR) to be ‘an increasingly serious
threat to global public health that requires action across
all government sectors and society’ [1]. It is estimated
that 700,000 deaths each year are due to drug-resistant
pathogens; by 2050, if no actions are taken to contain
AMR, this figure is predicted to rise to 10 million deaths
per year [2].
Inappropriate self-treatment and ‘just-in-case’ anti-
biotic prescribing practices, along with inadequate doses
and treatment duration, are considered the 5main con-
tributing causes of AMR [3, 4]. Optimizing the use of
antimicrobial agents is one of the four pillars of the
WHO Global Action Plan on AMR [5]. However, identi-
fying the causative agent of an infection, or at least dis-
tinguishing between bacterial and viral infections,
remains a challenge, as few diagnostics are suited to this
task and are not yet affordable for widespread use in
low- and middle-income countries (LMICs). Most health
facilities in LMICs lack the diagnostic capacity to cor-
rectly identify the cause of an acute febrile illness, thus
undermining a health worker’s ability to determine
whether an antibiotic is required or not [6]. To this end,
an adaptation in prescription practices needs to occur to
improve patient management by healthcare staff and to
change patient behaviours as well as treatment-seeking
behaviours. Success will mean making significant steps
toward achieving the dual goal of tackling AMR and
providing universal health coverage (UHC).
Recent work in LMICs has focused on unravelling the
diverse aetiologies of acute febrile illnesses especially in
children [7–13]. Data from outpatient settings are scarce,
with a small number of studies describing the relative dis-
tribution of bacterial, parasitic and viral agents among
acutely febrile patients [7]. These diagnoses often rely on
complicated serological and/or nucleic acid detection as-
says which are not available in primary healthcare centres,
where many ill patients first present for care. Currently,
there is a lack of quality-assured point-of-care tests
(POCTs) for many infectious causes of fever in LMICs.
Moreover, even when regulatory-approved POCTs are
available, there is, in many instances, a paucity of data on
their clinical usefulness within the operational contexts
found in these settings [14].
WHO, in its recent technical consultation on in vitro
diagnostics for AMR, has stressed the need for research
and development on additional tests that can distinguish
between bacterial and non-bacterial infections at pri-
mary healthcare facilities. In order to be fit for purpose,
such POCTs should be rapid diagnostic tests (RDTs)
such as lateral-flow tests or easy-to-use, robust diagnos-
tic platforms that use accessible, minimally invasive clin-
ical specimens (e.g. whole blood, urine stool or nasal
swabs) [15].
Practical solutions, adapted to LMICs, are needed to
provide better healthcare to patients presenting with fever,
allowing healthcare workers to confidently prescribe, or
not prescribe, an antibiotic based on the evidence of test
results. These solutions must be applicable now, with
existing tools, but also be amenable to incorporate newer
and better tools, when they become available.
In recent times, attempts have been made to build
antimicrobial stewardship programs into the healthcare
landscape in LMICs to correct inappropriate antimicro-
bial prescribing and use practices [16]. This cannot hap-
pen without a proper understanding of the bacteria that
are causing disease in the different countries, of how to
use currently available diagnostic tests and to incorpor-
ate these tests into clinical diagnostic algorithms and
how to modify practices and behaviours in order to cor-
rect ineffective management of acute febrile illnesses.
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The most appropriate platform for evaluating such inter-
ventions are research centres that are firmly integrated
within the health system, have access to clinical care fa-
cilities and have a platform for population-based evalu-
ation of immediate and long-term impact.
This is the basis for the intervention research study
described below. All the diagnostic tests described have
regulatory approval and are commercially available, but
have never been field-tested together, as part of
decision-making algorithms for use in peripheral health
facilities in LMICs.
This study is part of the FIND AMR Diagnostics Use
Accelerator, a platform which intends to stimulate stud-
ies to investigate the outcome of innovative clinical algo-
rithms using existing diagnostic kits and to inform
research into the design and implementation of effective
behavioural change interventions. The project comes at
an opportune time for institutions with the appropriate
capacity to integrate diagnostics into healthcare delivery
and to appropriately evaluate the impact.
Study objectives
This study aims to address the following question that is
based on the PICO process [17]:
In children and adolescents (+/− adults) who present
to outpatient clinics or peripheral health centres in
LMICs with acute febrile illness (Population), will intro-
ducing a package of available diagnostic tests, diagnostic
algorithms, new clinic process flows, and training and
communication for healthcare workers and patients or
caregivers (Intervention), as compared with current
practice (Control), improve case management of acute
febrile illnesses and better target the correct use of anti-
biotics (Outcome)?
– Primary study objectives: to assess the impact of a
package consisting of diagnostic tools, clinical
algorithms, and training and communication on (1)
clinical outcomes and (2) antibiotic prescriptions,
compared with routine practices for children and
adolescents (+/− adults in certain sites—see Table 1)
presenting at outpatient clinics.
– Secondary study objectives: to assess adherence (1)
to the new diagnostic algorithm by healthcare
workers, (2) to prescriptions by patients/caregivers,
and (3) to evaluate the safety outcomes of these
practices.
Explanation for choice of comparators
For this programmatic study, routine clinic processes
will serve as the comparator to the intervention package.
However, different to routine practice, both arms will
have a day 7 follow-up visit to the health facility.
Design and methods
Study settings
The study sites were identified through two calls for part-
ners: one for Africa and Asia (excluding India) [18], and
one for India only [19]. Applications were reviewed by
two respective selection committees who recommended
three sites in Africa, two in Asia and four in India; after
appropriate due diligence the sites were chosen. Informa-
tion on the sites is summarized in Table 1.
Study design
The study design captures a wide range of qualitative
contextual outcomes and quantitative empirical out-
comes in order to address the various aspects of the core
research question.
Overall, this is a prospective, comparative, multicountry
and multisite, open-label, two-armed, 1:1, randomized-
controlled trial which will compare the impact of the
intervention package (POCTs, clinical algorithm, clinic
process flow, and training and communication) on clinical
outcomes and antibiotic prescription patterns in febrile
patients with the current practice. All sites have adopted a
common protocol that reflects differences in patterns of
infection and behaviours at each site and in each geo-
graphical area.
As this is principally a site-level study, sample sizes
have been generated to provide the required statistical
power for each individual site. Analyses will be con-
ducted at two levels: first at the site level on individually
randomized study participants, and secondly, on the
combined studies as an aggregated-data meta-analysis
across all sites, with the site as the unit of analysis.
Study participants
The study will recruit children and adolescents (and
adults at some sites—Table 1) attending study site out-
patient facilities who present with an acute febrile illness
(current or within the past 7 days) defined as fever with
no focus or suspected respiratory tract infection (RTI).
Eligibility criteria
The study will include patients who meet all of the fol-
lowing criteria:
 Aged within the eligible range for the site (Table 1);
 Presenting with acute fever defined as having a
temperature of > 37.5 °C or a history of fever within
the last 7 days with no focus, or with suspected RTI;
 Lacking symptoms and signs of severe illness that
require hospital admission or referral as assessed by
the study clinicians;
 Informed consent for children under 18 years of age
provided by parent/guardian; patient assent required
for adolescents 18 years or older;
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 Willing to provide blood and other samples and to
adhere to study procedures explained in the
information sheet/consent forms following the
protocol;
 Available and willing to return for follow-up visit at
the health facility on day 7 (+/− 2 days)
Patients are excluded from the study if they fail to
meet any of the inclusion criteria listed above.
Data will also be gathered from healthcare workers
and patients/caregivers for the qualitative components,
where consent is provided.
Qualitative pre-intervention study
The qualitative study will be conducted to understand
the contextual factors and behavioural determinants af-
fecting adherence to prescriptions by patient/caregivers
and the associated communication about prescriptions
by healthcare workers. The findings will inform the
Training and Communication package which will be im-
plemented as part of the clinical intervention arm con-
sisting of diagnostic algorithms, POCTs, prescribing
decision trees, clinic process flow, training and commu-
nication on adherence to prescription. Further research
using the capacity, opportunity and motivation (COM-
B) model [20] together with the Theoretical Domains
Framework (TDF) [21] during the recruitment phase will
investigate the wider behaviour change implications of
adherence to prescription beyond the Training and
Communication package, as well as the long-term effects
of behavioural determinants for healthcare workers who
choose to use the clinical algorithms, new point-of-care
RDTs and associated prescribing practices.
Interventions
The trial intervention will consist of (1) diagnostic tests
(Table 2), (2) diagnostic and clinical algorithm (Fig. 1),
(3) training and communication of healthcare workers
and patients/caregivers and (4) clinic process flow.
Diagnostic tests
The diagnostic tests to be used in the intervention pack-
age (Table 2) will be selected based on local needs.
Non pathogen-specific POCTs:
 White blood cell total and differential counts (WBC/
diff)
 Urine dipstick
 C-reactive protein (CRP)
Diagnostic and clinical algorithm
Healthcare workers will follow a country-specific algo-
rithm for cases in the intervention arm, which takes into
account the specific tests to be used at the site. A typical
clinical algorithm is outlined in Fig. 1. Notably, the deci-
sion on pathogen-specific diagnostic tests to use in each
case was based on clinical presentation, which we have
grouped into respiratory and non-respiratory signs and
symptoms. In addition, clinical decisions in the interven-
tion arm will be supported by CRP and WBC/diff POCT.
Training and Communication package
Communication messages about adherence to prescrip-
tion are delivered by healthcare worker(s) to the study
patient or caregiver in the intervention arm. The method
of delivery of the communication message will be site-
specific, depending on the roles of different types of
healthcare workers, and behavioural determinants iden-
tified in the qualitative analysis. Training is provided to
healthcare workers to deliver the communication mes-
sages; together, the training and delivery of the messages
make up the Training and Communication package de-
veloped for each site based on findings from the qualita-
tive work identifying behavioural drivers of adherence to
Table 2 Pathogen-specific point-of-care (POC) tests
Pathogen Type of test
Dengue virus Lateral flow RDT: detects Dengue virus NS1 antigen and IgM (and IgG) from serum or whole blood
Streptococcus pyogenes Lateral flow RDT: detects group A streptococcal antigen from throat swabs
Salmonella enterica serovar Typhi Lateral flow RDT: detects Salmonella typhi-specific IgM from serum or whole blood
Orientia tsutsugamushi (scrub typhus) Lateral flow RDT: detects Orientia tsutsugamushi antibodies (IgG, IgM, and IgA) in human serum,
plasma, whole blood
Influenza virus Lateral flow RDT: detects influenza virus type A, type B and A(H1N1) pandemic antigens directly from
nasal/throat/nasopharyngeal swab or nasal/nasopharyngeal aspirate
Chikungunya virus Lateral flow RDT: detects Chikungunya virus IgG/IgM antibodies in serum, plasma or whole blood
Streptococcus pneumoniae Lateral flow RDT: detects S. pneumoniae antigen in the urine of patients with pneumococcal pneumonia
Respiratory syncytial virus Lateral flow RDT: detects respiratory syncytial virus (RSV) fusion protein antigen in nasal wash and
nasopharyngeal (NP) swab specimens
Leptospira interrogans (leptospirosis) Lateral flow RDT: detects Leptospira interrogans IgM antibodies from urine
Plasmodium Sp. (malaria) Lateral flow RDT as per national guidelines
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prescriptions. The delivery of the core communication mes-
sage will be personalized to the individual patient (e.g. adjust-
ing emphasis, but not message content), based information
collected from the patient before clinical assessment.
Clinic process flow
At the majority of sites, the clinic process flow described
below, closely follows the normal clinic flow, only with
minor changes to speed up the process, such as mecha-
nisms to minimize queuing.
Participant flow
The participant flow is shown in Fig. 2. Patients present-
ing at the clinic will be pre-screened for fever and those
meeting the study eligibility criteria will be enrolled in
either the control or intervention arm of the study by
simple, 1:1 randomization. Participants in both arms will
be seen by clinicians who will collect patient histories
and conduct clinical examinations.
Patients in the control arm will follow routine diagnos-
tic and treatment procedures for acute febrile illness as
outlined in each clinic. Patients in the intervention arm
will first be asked to provide information on their atti-
tude towards the use of antibiotics, and then undergo a
provisional diagnosis (respiratory/non-respiratory). Sam-
ples will be taken from patients to be performed using
POCTs and any other tests based on the provisional
diagnosis and algorithm. An additional communication
package to influence adherence to prescription will be
provided by the study team (clinicians, pharmacist and/
or nurses) before the patient leaves the facility.
All patients in both the intervention and control arms
will be followed up on day 7 (+/− 2) in the health facilities,
to reassess their health status and prescription adherence.
Patients who do not improve following the day of en-
rolment will need to visit the health facilities making an
unscheduled visit before the day 7 (+/− 2) follow-up visit
for further assessment and management.
The package of POCTs provided in the intervention arm
is considered to be an addition to tests provided in routine
care. Therefore, where site routine protocols include the
use of blood culture or other laboratory tests, these will also
be conducted in the intervention arm (along with the nor-
mal practice in the control arm). Patients will return to the
clinic for review of their prescription in light of these test
results, following the normal schedule.
Biological specimens
Biological samples will be handled as outlined below:
 Two millilitres of venous blood samples will be
taken from adult patients and children over 5 years
of age, as per the Seattle Children’s Hospital
Guidelines (no venous sample will be taken from
patients weighing less than 4 kg and less than
5 years for safety reasons).
 For children under 5 years of age, finger prick blood
will be taken instead of 2 mL venous blood. The
blood sample will be used for PoC tests (CRP, Hb
Fig. 1 Outline of diagnostic and clinical algorithm. RSV, respiratory syncytial virus; GAS, group A streptococci; CRP, C-reactive protein; WBC/DIFF,
white blood cells total counts/differential counts; Rx, treatment; ATB, antibiotic; Y, prescribe antibiotic; N, antibiotic prescription not warranted; P,
antibiotic prescription possible if clinically indicated
Salami et al. Trials          (2020) 21:974 Page 6 of 13
and white cell differential and pathogen specific
rapid tests) as per clinical algorithms and SOPs
adapted from product manufacturers’ user
manuals.
 A nasopharyngeal swab will be taken from patients
who need to be tested for influenza or respiratory
syncytial virus or both as per clinical algorithm and
SOPs adapted from product manufacturers’ user
manuals.
 A throat swab will be taken from patients with
pharyngitis/pharyngitis and tested as per clinical
algorithm and SOPs adapted from product
manufacturers’ user manuals
 A urine sample will be taken for patients with
suspect of urinary tract infection or who need
Streptococcus pneumoniae urine antigen tests
(adults) and tests performed as per SOPs adapted
from product manufacturers’ user manuals.
 Repeat or unscheduled samples may be taken for
safety reasons or for technical issues with the
samples.
 All unused samples will be destroyed according to
national or site-specific sample destruction
guidelines.
 No biological samples will be stored.
Strategies to improve and assess adherence
Patients and caregivers in the intervention arm (but not
the control arm) will receive a communication message
in support of adherence to the prescription, based on
the local research findings described above. The method
of delivery of the communication message will be site-
specific, depending on the roles of different types of
healthcare workers, and the behavioural determinants
identified in the qualitative analysis.
The delivery of the core communication message will
be personalized to the individual patient (e.g. adjusting
emphasis, but not message content), based on a small
amount of information collected from the patient before
clinical assessment.
All patients in both the intervention and control arms
will be followed up on day 7 (+/− 2) in the health facil-
ities to reassess their health status and adherence to pre-
scription. Information on adherence to prescription will
be collected using qualitative in-depth interviews with
the patient and through pill counts (participants/care-
givers will be asked to bring back packaging and
remaining medicine on day 7). This includes assessing
the behaviour of patients who were not prescribed medi-
cation to find out if they obtained any antibiotics or any
other treatment, the reasons for this and where the anti-
biotics or other treatment were obtained.
All enrolled participants (and caregivers, in case of
children) will be reminded prior to departure on day 0
to visit the health facilities if their illness worsens before
day 7. All participants who do not return on day 7 will
be followed up via telephone to assess their well-being
and the need to return to the clinic for the end of study
assessment. Where feasible and where consent was pro-
vided by study participants at enrolment, the investiga-
tors will conduct home visits if the patient is unable to
return to the clinic for the day 7 follow-up visit.
Fig. 2 Study participant flow
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Adherence to the diagnostic algorithm will be evaluated
by reviewing the case report forms (CRFs) to assess
algorithm-driven use of POCTs and antibiotic prescriptions.
Study outcomes
The primary outcome measures are the point estimates
of:
1 The proportion of cases of acute febrile illness with
favourable outcome (defined as being alive + no
fever + resolution of day 0 symptoms) on day 7, in
both arms.
2 The proportion of antibiotic prescriptions for acute
febrile illness in the two arms. Specifically, the study
intends to detect a reduction (at least 30% from the
baseline) in unnecessary antibiotic prescribing,
without adversely affecting clinical outcomes. While
antibiotic prescription rates are known at the study
sites, outcomes are not currently known because
patients are not routinely followed-up.
The secondary outcomes are:
1 Proportion of patients prescribed antibiotics at clinics
who describe adherence to prescription on day 7.
2 Proportion of healthcare workers who adhered to
new algorithm.
3 Proportion of participants experiencing adverse
events (see description in Safety reporting section).
Participant timeline
The schedule of events is described in Table 3.
Sample size estimation
The sample size calculations were based on criteria that
would allow evaluation of antibiotic prescribing at each
site.
The sample size was calculated for each country in
order to detect a 30% difference (with a 95% confidence
interval of +/− 5%) in the antibiotic prescription propor-
tions compared with the initial proportion without the
intervention, with a power of at least 80% to detect such
a precision estimate (Fig. 3). The minimal theoretical
sample size obtained for each site [20] has been in-
creased by 10% to allow for loss to follow-up.
Estimates of the current proportion of patients pre-
scribed antibiotics for acute febrile illnesses at different
clinics in each country study were used as the basis to
calculate the required sample size (Table 4).
Sample sizes are considered a minimum. Enrolment
will continue after the sample size has been reached,
through the 12months of the intervention, to allow for
seasonal variations.
Strategies for achieving adequate participation enrolment
We estimate, based upon clinic registries for the previ-
ous 1 or 2 years, that there will be adequate enrolment
of participants in all of the sites.
Assignment of interventions
Enrolled patients will be randomized into either the
intervention or the control arm. Patients in the interven-
tion arm will be managed with a package of interven-
tions (as detailed above) and patients in the control arm
will be managed as per routine clinical practice.
Patients will be randomized centrally, by site, into the
intervention or control arm in a 1:1 allocation ratio.
Randomization codes will be prepared by the trial data
manager based on the sample size estimates for each site
and will be sent prior to commencement of enrolment
to each site.
Blinding and masking
Not applicable as this is an open label study.
Data management
All anonymized clinical participant data relating to the
trial will be recorded in electronic CRFs created on the
Table 3 Timeline for study participants
Schedule of events
Day 0 visit Day 7 visit (+/− 2 days) Unscheduled visit
Informed consent and enrolment x
Demographic data collection x
History/physical examination x x x
Diagnostic tests x
Treatment prescription x x
Patient adherence evaluation x x
Collection of qualitative data x x
Delivery of communication messages x
Adverse event monitoring (see Safety reporting section) x x
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study sponsor’s online clinical trials platform (OpenCli-
nica Enterprise Edition version 4.0). The sponsor will
provide training on CRF completion prior to the start of
the study. Electronic data capture (EDC) will be per-
formed via eCRFs on android tablets in offline mode, to
facilitate data entry at peripheral sites with limited inter-
net connections, and synchronized daily at site research
offices with verified, reliable internet connections. Paper
CRFs will be available as back-up. Only authorized study
personnel will have access to the CRFs. Consent forms
containing patient identifying data will be retained at
each site and kept in secure lockable cabinets in a secure
room with restricted access.
Records and documents, including signed informed
consent forms (ICF) pertaining to the conduct of this
trial will be retained by the principal investigator for 10
years after trial completion, unless local regulations or
institutional policies require a longer retention period.
Data quality
Training on the protocol, Good Clinical Practice (GCP),
Good Clinical Laboratory Practice (GCLP) and the use
of the diagnostic tests will be provided by the sponsor
and University of Oxford. A laboratory manual, which
describes all of the sample testing procedures, will be
provided by FIND prior to the commencement of the
trial. Detailed training on the EDC system will be pro-
vided by the data manager prior to first participant en-
rolment at each site. All of the POCT results will be
photographed following a standard operating procedure.
These photographs will be uploaded into the CRF to en-
sure the quality of the POCT data being recorded in the
Table 4 Baseline antibiotic prescription rates for acute febrile illnesses
Country Expected antibiotic prescription
rate in control arm (based on
historic prescribing)







Nepal 55% 30% 1760 1760 3520
Uganda 73% 30% 1200 (combined) 2400
Ghana 43% 30% 1383 n/a 2766
Burkina Faso 77% 30% 859 n/a 1718
Myanmar 43% 30% 440 440 1760
India JSS 50% 30% 864 n/a 1728
India PGIMER 50% 30% 864 864 3456
India RD Gardi 20% (children), 40% (adults) 30% 553 831 2768
India NICED 50% 30% 880 n/a 1760
Total 21,876
Fig. 3 Sample size chart
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database and so that corrective procedures can be
followed should there be any discrepancies between the
laboratory staff and the monitor, since a patient’s on-
going care is based on these results. The sponsor will
perform risk-based monitoring of this trial, and associ-
ated quality control checks in line with ICH GCP, and
all applicable regulatory requirements.
Training on qualitative methods of data collection,
analysis and use of the behaviour change wheel [21]
process will be provided by the University of Oxford
and/or onsite social science leads.
Statistical methods
We have a dedicated SAP that is currently under review
that will cover the statistical analysis in great detail, fo-
cusing not only on the country-specific analyses, but also
on the overall analysis from the combination of the data
from all countries. We foresee the analysis to need some
country-specific adjustments. However, here is an over-
view of the analyses we will perform.
Populations for statistical analyses
Table 5 describes the study populations for the purposes
of analyses.
Descriptive statistics
Descriptive statistics tables will be generated to
summarize the characteristics of the participants. The
number of participants included and excluded will be re-
ported. Among the included participants, the information
will be broken down by site, sex, and age group. Results
will be reported either in absolute numbers (e.g. number
of subjects in a group) or summarized by mean, median,
standard deviation, minimum, maximum and quartiles.
Efficacy analyses
The point estimates of the study outcomes (percentage
of antibiotic use, percentage reduction from baseline),
with a 95% confidence interval based on the Wilson
score interval, will be calculated for (1) clinical outcome
(favourable or unfavourable), (1a) between-arms and
(1b) between compliant and compliant patients within
arms and for (2) antibiotic use, also (2a) between-arms
and (2b) within-arms.
Analysis of endpoints
The endpoints of the trial will be evaluated as follows:
– The proportion of cases with a favourable outcome
in the two arms, in the mITT and PP population
– The proportion of compliant cases with a favourable
outcome in the PP population
– The proportion of inappropriate antibiotic
prescription in the PP population
– The antibiotic prescription rate in the two arms, in
the mITT and PP populations




We will calculate the combined proportion of compliant
participants with favourable outcomes and non-
compliant participants with unfavourable outcomes
within each arm.
Additionally, the ratio of the proportion of compliant
participants with a favourable outcome versus the pro-
portion of non-compliant participants with an unfavour-
able outcome will be reported as relative risk.
There is no planned interim analysis.
Handling of missing data
Missing and invalid data for key measures that contrib-
ute to the evaluation of each of the outcomes will be re-
ported in summary tables and will not be imputed. The
primary outcomes do not involve quantitative assess-
ments, and therefore, we feel it would not be appropriate
to input data. Data from participants for whom partial
data are available will be included in the analysis of spe-
cific outcomes, provided the data allow to evaluate them
(e.g. adherence to prescription).
Data and safety monitoring board
Given that the clinical decision to prescribe or not pre-
scribe antibiotics in the intervention arm of the study
will be guided by the intervention package, there is a
possibility that the diagnostic algorithm may fail to de-
tect a need for antibiotics in some participants, thereby
exposing them to the risk of getting worse from disease.
Table 5 Populations for statistical analyses
Population Description
1. Enrolled All participants who sign the ICF
2. Randomly assigned to trial intervention (RAI) Randomized to either intervention or control arm
3. Modified intent to treat (mITT) Participants in RAI with partial data (but not fully compliant with the protocol)
4. Evaluable per protocol population (PP) All participants who fully complied with the protocol
5. Safety population for analysis All participants randomly assigned to trial intervention.
Participants will be analysed according to the intervention they actually received.
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It is also possible that routine procedures might expose
patients to risks, such as those related to inappropriate
use of antibiotics or missed diagnosis, which we will
monitor, but we will not change the routine care for the
patients in the control arm during the trial.
Therefore, we have established a data safety monitor-
ing board (DSMB), composed of experts, many of whom
are based in LMICs with experience in paediatrics, trop-
ical infectious diseases, statistics, clinical trials and social
science work.
The DSMB will evaluate ongoing safety data, assess
the risks and benefits and give recommendations on
whether to continue, amend or stop the trial. The DSMB
will review, at agreed intervals, the following data as they
relate to the study progress and participant safety:
 Number of screened patients, by study site
 Number of included patients, by study site and by
study arm
 Patients’ baseline characteristics
 Number of patients withdrawn and lost to follow-
up, by study site and by study arm and reasons for
withdrawal
 Number of serious adverse events (deaths and
hospitalisations) by study arm
Safety reporting
ICH definitions of adverse events (AEs) in this study will
be interpreted in light of the lack of testing for any new
diagnostic or medicinal product.
We will capture untoward events occurring during the
period under observation in order to understand if either
approach (current practice vs. new package of interven-
tions) might be associated with a risk to the patient’s
welfare (e.g. unnecessary use of antibiotics that could
cause AEs; conversely, a practice that denies a patient a
treatment that was otherwise warranted).
Non-serious AEs are to be reported on the CRF. In
addition, each site principal investigator will be respon-
sible for reporting serious adverse events (SAE) to the
sponsor (FIND) within 24 h as well as to the Ethics Re-
view Committee with which they are associated, depend-
ing on the local requirements.
Ethical approvals
The overall protocol has been approved by the Oxford
University Tropical Research Ethics Committee
(OxTREC number 52-19). Each of the country-specific
protocols is also approved by national and/or institu-
tional ethics committees in Burkina Faso, Ghana,
Uganda, India, Nepal and Myanmar* (*final document
pending at the time of writing).
Informed consent
Informed consent will be obtained by the healthcare
workers/social scientists from all participants and/or
their legally authorized representatives/caregivers prior
to their participation in the study. Patient information
sheets and consent forms have been developed in Eng-
lish and translated into local languages within the re-
spective study sites. Participants or their parents/
caregivers will be required to sign and date a statement
of informed consent that meets the requirements of the
ethics review committees.
A copy of the ICF(s) will be given to the participant or
the participant’s parents/caregivers.
Protocol amendments
We will share information on important protocol modi-
fications (e.g. changes to eligibility criteria, outcomes,
analyses) with the investigators, REC/IRBs, trial partici-
pants, trial registries, journals and regulatory agencies.
Confidentiality
Participants will be assigned a unique identifier or study
number. Any participant records or datasets that are
transferred to FIND will contain the identifier only; par-
ticipant names and any information which would iden-
tify the participant will not be transferred.
The patient study number will be on all labels, data col-
lection sheets and in the database to maintain confidenti-
ality, including in the CRF. All documents relating to the
clinical study will be stored securely electronically within
OpenClinica and will only accessible by study staff and au-
thorized personnel. The study will comply with the Gen-
eral Data Protection Regulation (GDPR), which requires
that personal data must not be kept as identifiable data for
longer than necessary for the purposes concerned. All
qualitative data will be stored at the sites.
Access to data
Only trial staff in country will have access to the data for
each country. Only FIND as study sponsor, and Oxford,
as study collaborator, will have access to the anonymized
data collected at all of the sites. FIND will perform the
meta-analysis following the statistical analysis plan.
Ancillary and post-trial care
The study aims to evaluate clinical outcomes and anti-
biotic prescription rates for acute fevers 7 days post-
enrolment and does not provide specific therapeutic in-
terventions beyond the marketed and approved medica-
tions which will be prescribed by the treating physicians
based on either routine practice or the new diagnostic
package. For participants who experience complications
from an acute febrile illness in either arm of the study,
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resources will be provided to manage these, in line with
the national guidelines in each country.
Dissemination policy
The publication policy follows the ICMJE guidelines
[22]. Both the protocol and the study outcomes will be
published in peer-reviewed, open-access journals, and
the data will be made available. We intend to publish
both the individual study results and the aggregated-data
meta-analysis. We will also publish the qualitative meth-
odologies and results for the study as a whole, as well as
for the individual studies.
We also intend to prepare policy briefs and summaries
as required for policy makers at both country and inter-
national level, in order to inform guideline development
and policy.
Discussion
The FIND AMR Diagnostics Use Accelerator is a plat-
form to evaluate a package of interventions and provide
evidence to inform policy change that can positively im-
pact antimicrobial resistance (AMR) and contribute to
universal health coverage (UHC).
This article presents the rationale, methods, and pro-
cedures of a large multicounty clinical trial in which we
aim to investigate whether adopting a package of avail-
able POCTs, clinical diagnostic algorithms, clinic process
flow adjustments, and training and communication ac-
tivities can result in improved care of acute febrile illness
and more rational antibiotic prescribing and use.
Many published studies that evaluate infectious febrile
illnesses are conducted over only a few months, and
therefore do not adequately account for seasonal varia-
tions in such illnesses [6], representing a major meth-
odological weakness. We aim to address this by ensuring
a 12-month study period which captures seasonal varia-
tions in infectious diseases in the study countries.
The study will focus on cases presenting at peripheral
health facilities and hospital outpatient departments as
this is generally the first encounter that patients have
with the healthcare system where antibiotics can be pre-
scribed. These cases represent a sample of community-
acquired infections which are serious enough to seek
treatment, but not serious enough to require
hospitalization. The study in some sites targets children
and adolescents as a recognized vulnerable group, while
other sites have included adult participants for broader
population representation (see Table 1).
There are a limited number of POCTs that could be de-
ployed and used at peripheral health centres to help differ-
entiate between bacterial and viral infections (host
biomarkers) or diagnose a specific bacterial or viral agent
(pathogen-specific tests). To identify suitable candidates,
we undertook a landscape scoping analysis of available
POCTs and matched this analysis with the prevalent in-
fections reported by the participating study sites.
It is anticipated that conditions will vary in different
study settings, and the overall package of interventions
has been adapted to local background infection profiles
and practices. Therefore, the study has a common tem-
plate protocol, which is tailored to the conditions of par-
ticipating study sites. This will allow to draw both
locally-relevant and generally-applicable conclusions as
to the utility of the proposed package of interventions.
The FIND AMR Diagnostics Use Accelerator could
potentially serve as a pathfinder for generating evidence
that will inform policy change and lay the groundwork
for a robust route to diagnostic uptake and thus posi-
tively impact patient care globally.
Trial status
The study protocol reflects approved version 1.4 from
20 December 2019. Recruitment at the first site will
commence in July 2020 and is expected to be completed
across all sites in December 2021.
Name and contact information of the trial sponsor
Foundation for Innovative new Diagnostics (FIND)
Campus Biotech
Chemin des Mines 9
1202 Geneva, Switzerland
Role of study sponsor and funding agency
This research is funded by the Swiss Agency for Development and
Cooperation, Global Health Division, Contract number 810571721 titled
‘Advancing access to better diagnostics for febrile childhood illnesses’ and a
Memorandum of Understanding between the UK Government Secretary of
State for Health and Social Care and FIND. The Indian Council for Medical
Research (ICMR) also contributes funds for the Indian study sites. The funders
had no role in study design, data collection and analysis, decision to publish
or preparation of the manuscript. FIND is also using core funding and
internal resources to manage the programme. As the study sponsor, FIND
will coordinate the collection and management of data, perform the primary
analysis and lead interpretation of the data and writing of the report. It will
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Ethics approval and consent to participate
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(*final document pending at the time of this writing). This trial is also regis-
tered with ClinicalTrials.gov (Identifier: NCT04081051). We will obtain written
informed consent from all caregivers/adult patients and written informed
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